At what enterprise value was LADR – LABORATORY GROUP DR. KRAMER & COLLEAGUES acquired in 2024?

During the acquisition of LADR – LABORATORY GROUP DR. KRAMER & COLLEAGUES by SONIC HEALTHCARE in 2024, the company was valued at an estimated revenue multiple of below 5x. The transaction's Enterprise Value is estimated to be in the range of 300M - 700M EUR. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 13.4x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of LADR – LABORATORY GROUP DR. KRAMER & COLLEAGUES when it was acquired by SONIC HEALTHCARE?

The estimated EV/EBITDA multiple for LADR – LABORATORY GROUP DR. KRAMER & COLLEAGUES is in the range of 5x - 12x. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 13.4x. Join our community for free to access full valuation data and industry trends.

What was the revenue of LADR – LABORATORY GROUP DR. KRAMER & COLLEAGUES at the time of the deal?

The revenue of LADR – LABORATORY GROUP DR. KRAMER & COLLEAGUES at the time of the deal is estimated to be in the range of 250M - 500M EUR. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of LADR – LABORATORY GROUP DR. KRAMER & COLLEAGUES during the acquisition?

LADR – LABORATORY GROUP DR. KRAMER & COLLEAGUES's EBITDA is estimated to be in the range of 50M - 100M EUR. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the LADR – LABORATORY GROUP DR. KRAMER & COLLEAGUES acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the LADR – LABORATORY GROUP DR. KRAMER & COLLEAGUES deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://investors.sonichealthcare.com/DownloadFile.axd?file=/Report/ComNews/20241209/02891934.pdf

← DATABASE

Home Database Healthcare & PharmaLADR – LABORATORY GROUP DR. KRAMER & COLLEAGUES

12/2024

LADR – LABORATORY GROUP DR. KRAMER & COLLEAGUES

Acquired by

SONIC HEALTHCARE

GERMANY Health Providers / Healthcare Facilities / Labs (Biology) EV 300M - 700M EUR

LADR – LABORATORY GROUP DR. KRAMER & COLLEAGUES acquired by SONIC HEALTHCARE

GERMANY Health Providers / Healthcare Facilities / Labs (Biology) EV 300M - 700M EUR

Context

Sonic Healthcare has signed binding agreements to acquire the LADR Laboratory Group, marking a substantial expansion of its German and European diagnostic footprint. The transaction was structured on a cash and debt-free basis, with a total consideration satisfied through a mix of Sonic ordinary shares (up to 222 million euros) and cash funded from existing facilities. The strategic rationale centers on the strong cultural and operational alignment between the two organizations, with significant synergy potential identified in procurement, laboratory overlaps, logistics, and equipment maintenance. The deal also includes an inherited put/call structure for a separate German laboratory business, expected to be fully consolidated by 2027. Following the acquisition, the target's senior leadership, including the CEO and Medical Director, will remain with the group to lead the integration collaboratively with the acquirer’s German division.

LADR – LABORATORY GROUP DR. KRAMER & COLLEAGUES, which reported an EBITDA margin of LOGIN in 2024, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a LOGIN to the average currently observed in the Healthcare & Pharma sector (13.4x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

LADR is one of the top five medical laboratory groups in Germany, providing high-quality diagnostic testing services through a national network of stand-alone and hospital-based laboratories. Founded in 1945 and managed by the third generation of the Kramer family, the group's business model is predominantly focused on medical laboratory revenue (80% of total), supplemented by medical supplies trading, logistical services, and a specialized clinical services division focused on women’s health. The group maintains a significant international footprint, including "badaj.to," the fourth largest laboratory group in Poland, and a joint-venture interest in Finland. Operating with over 2,800 full-time staff, LADR leverages a centralized laboratory hub in Geesthacht to provide comprehensive diagnostic solutions across the German healthcare landscape, emphasizing medical leadership and high-quality clinical outcomes.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2024

2023

Other operations with LADR – LABORATORY GROUP DR. KRAMER & COLLEAGUES

REFERENCES

Valuation range: EV 300M - 700M EUR

Revenue range: 250M - 500M EUR

EBITDA range: 50M - 100M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of LADR – LABORATORY GROUP DR. KRAMER & COLLEAGUES by SONIC HEALTHCARE are reserved for mynth community members. Register for free to unlock full data.

Authors: mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).